EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase IV)Open Access · CC BY-NC 4.0

The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study

Jun Sung Moon, Il Rae Park, Sang Soo Kim, Hye Soon Kim, Nam Hoon Kim, Sin Gon Kim, Seung Hyun Ko, Ji Hyun Lee, Inkyu Lee, Bo Kyeong Lee, Kyu Chang Won

Diabetes & Metabolism Journal · 2023

DOI: 10.4093/dmj.2023.0171 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes & Metabolism Journal, 2023. Verfasst von Jun Sung Moon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Hypercholesterolemia, Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Yuhan Co. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To investigate the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe combination compared to highintensity rosuvastatin in high atherosclerotic cardiovascular disease (ASCVD) risk patients with type 2 diabetes mellitus (T2DM).

Methods

This study was a randomized, multicenter, open, parallel phase 4 study, and enrolled T2DM subjects with an estimated 10-year ASCVD risk ≥7.5%. The primary endpoint was the low-density lipoprotein cholesterol (LDL-C) change rate after 24-week rosuvastatin 10 mg/ezetimibe 10 mg treatment was non-inferior to that of rosuvastatin 20 mg. The achievement proportion of 10-year ASCVD risk

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anticholesteremic AgentsHypercholesterolemiaDiabetes Mellitus, Type 2Cardiovascular DiseasesAtherosclerosisHumansRosuvastatin CalciumEzetimibeCholesterol, LDLDrug Therapy, Combination

Stichwörter der Autor:innen

Cardiovascular diseasesDiabetes mellitus, type 2Drug therapy, combinationEzetimibeRosuvastatin calcium

Substanzen

Rosuvastatin CalciumEzetimibeCholesterol, LDLAnticholesteremic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
  • Department of Internal Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
  • Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
  • Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.

Förderung

  • Yuhan Co. Ltd.

Zitieren

APA

Moon, J. S., Park, I. R., Kim, S. S., Kim, H. S., Kim, N. H., Kim, S. G., Ko, S. H., Lee, J. H., Lee, I., Lee, B. K., & Won, K. C. (2023). The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2023.0171

Vancouver

Moon JS, Park IR, Kim SS, Kim HS, Kim NH, Kim SG, et al. The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study. Diabetes & Metabolism Journal. 2023. doi:10.4093/dmj.2023.0171

BibTeX
@article{Moon2023,
  author = {Moon, Jun Sung and Park, Il Rae and Kim, Sang Soo and Kim, Hye Soon and Kim, Nam Hoon and Kim, Sin Gon and Ko, Seung Hyun and Lee, Ji Hyun and Lee, Inkyu and Lee, Bo Kyeong and Won, Kyu Chang},
  title = {The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study},
  journal = {Diabetes & Metabolism Journal},
  year = {2023},
  doi = {10.4093/dmj.2023.0171}
}
Kostenlos starten →